New trial + clinical hiring Started a Phase 2 trial (NCT07570862, actual start Jul 27, 2026); since then posted 1 clinical-operations role. ClinicalTrials.gov NCT07570862 (Jul 27, 2026)Evidence (1 event)
Jul 27, 2026 · ClinicalTrials.gov NCT07570862 leadSponsor.name='Fate Therapeutics'; phases=['PHASE2']; overallStatus=RECRUITING; startDateStruct={date:2026-07-27,type:ACTUAL}; studyFirstPostDate=2026-05-06; briefTitle='A Phase 2, Open-Label, Single-Arm Trial of FT819 in Participants With Lupus Nephritis'
Grant Government grant: $15M (total, as published), announced Sep 25, 2026. Source: SEC filing. source ↗
Trial start 2: A Phase 2, Open-Label, Single-Arm Trial of FT819 in Participants With Lupus Nephritis source ↗
Trial start Phase 1: FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors source ↗
Trial start 1: A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease source ↗
Trial start Phase 1: FT825/ONO-8250, an Off-the-Shelf, HER2 CAR-T, With or Without Monoclonal Antibodies in Advanced Solid Tumors source ↗
Trial start Phase 1: FT522 With Rituximab in Relapsed/Refractory B-Cell Lymphoma (FT522-101) source ↗
Trial start Phase 1: FT596 in Combination With R-CHOP in Subjects With B-Cell Lymphoma source ↗
Trial start Phase 1: FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors source ↗
Trial start Phase 1: FT576 in Subjects With Multiple Myeloma source ↗
Trial start Phase 1: FT538 in Combination With Monoclonal Antibodies in Advanced Solid Tumors source ↗
Trial start Phase 1: FT819 in Subjects With B-cell Malignancies source ↗
Trial start Phase 1: FT538 in Subjects With Advanced Hematologic Malignancies source ↗
Trial start Phase 1: FT516 in Combination With Monoclonal Antibodies in Advanced Solid Tumors source ↗
Trial start Phase 1: FT596 as a Monotherapy and in Combination With Anti-CD20 Monoclonal Antibodies source ↗
Trial start Phase 1: FT516 in Subjects With Advanced Hematologic Malignancies source ↗
Trial start —: Long-term Follow-Up Study Following Treatment With Fate Therapeutics' Engineered Cellular Immunotherapy source ↗
Trial start —: Long-term, Non-interventional, Observational Study Following Treatment With Fate Therapeutics FT500 Cellular Immunotherapy source ↗
Trial start Phase 1: FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors source ↗
Trial start Phase 1: FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid Tumors source ↗
Trial start Phase 1/Phase 2: Study of ProTmune for Allogeneic HCT in Adult Patients With Hematologic Malignancies source ↗
Trial start Phase 1: A Trial of a Single ProHema-CB Product Transplant in Pediatric Patients With Inherited Metabolic Disorders source ↗
Trial start 1: A Phase 1 Trial of a Single ProHema® CB Product for Pediatric Patients With Hematologic Malignancies source ↗
Trial start Phase 2: The PUMA Trial is a Trial of a Single ProHema Modulated-Cord Blood (CB) Unit as Part of a Double CB Transplant in Patients With Hematologic Malignancies. source ↗
Showing 25 of 27 dated events.
Upcoming milestones
Sep 30, 2027 (ESTIMATED) · 1 · A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease · NCT06308978
2028-01 (ESTIMATED) · Phase 1 · FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors · NCT07216105
May 1, 2029 (ESTIMATED) · Phase 1 · FT825/ONO-8250, an Off-the-Shelf, HER2 CAR-T, With or Without Monoclonal Antibodies in Advanced Solid Tumors · NCT06241456
Jul 1, 2029 (ESTIMATED) · 2 · A Phase 2, Open-Label, Single-Arm Trial of FT819 in Participants With Lupus Nephritis · NCT07570862
Estimated primary completion per ClinicalTrials.gov. Dates move.
Level (Entry/Mid/Senior/Executive) is estimated from the job title and required years of experience. Descriptions are short excerpts (about the first 60 words) of the posting plus skills picked out of it; use Read full posting for the complete text.
Funding
Last 2 years.
Government grant: $15M (total, as published), announced Sep 25, 2026. Source: SEC filing. source ↗
The PUMA Trial is a Trial of a Single ProHema Modulated-Cord Blood (CB) Unit as Part of a Double CB Transplant in Patients With Hematologic Malignancies.
